How to avoid compulsory licensing – COVID or not Biopharma companies can minimise the threat of compulsory licensing by taking strategic steps that benefit both business and patients, says April Abele Isaacson of Kilpatrick Townsend By April Abele Isaacson November 24 2021
Patent paradox: using global strategy to protect country-specific assets The globalisation of the biopharma industry has made it increasingly essential for companies to consider parallel patent proceedings across multiple countries, as April Abele Isaacson of Kilpatrick Townsend explains By April Abele Isaacson November 05 2021
